Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC42 bridging study in healthy Chinese subjects
NCT04965337Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of asc42 in Nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC) and hepatitis B (HBV) (4 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Area Under the Curve up to 4 days and Maximum Plasma Concentration up to 4 days. Started Jul 2021; status: completed.
02
Drugs
asc42
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04965337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965337.